Cardiff Oncology Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Cardiff Oncology's revenue and earnings are forecast to decline at 32.6% and 29% per annum respectively while EPS is expected to decline by 19.8% per annum.
Anahtar bilgiler
-29.0%
Kazanç büyüme oranı
-19.8%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 27.1% |
| Gelir büyüme oranı | -32.6% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 06 Sep 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -77 | -62 | -67 | 4 |
| 12/31/2025 | 0 | -57 | -49 | -48 | 5 |
| 12/31/2024 | 1 | -47 | -43 | -38 | 5 |
| 6/30/2024 | 1 | -41 | -32 | -32 | N/A |
| 3/31/2024 | 1 | -40 | -31 | -30 | N/A |
| 12/31/2023 | 0 | -41 | -31 | -31 | N/A |
| 9/30/2023 | 0 | -41 | -34 | -33 | N/A |
| 6/30/2023 | 0 | -40 | -33 | -33 | N/A |
| 3/31/2023 | 0 | -39 | -33 | -32 | N/A |
| 12/31/2022 | 0 | -39 | -35 | -34 | N/A |
| 9/30/2022 | 0 | -39 | -33 | -32 | N/A |
| 6/30/2022 | 0 | -38 | -30 | -30 | N/A |
| 3/31/2022 | 0 | -34 | -28 | -27 | N/A |
| 12/31/2021 | 0 | -28 | -23 | -23 | N/A |
| 9/30/2021 | 0 | -25 | -21 | -21 | N/A |
| 6/30/2021 | 0 | -23 | -19 | -19 | N/A |
| 3/31/2021 | 0 | -24 | -19 | -19 | N/A |
| 12/31/2020 | 0 | -23 | -17 | -16 | N/A |
| 9/30/2020 | 0 | -20 | -15 | -14 | N/A |
| 6/30/2020 | 0 | -20 | -14 | -14 | N/A |
| 3/31/2020 | 0 | -17 | -13 | -13 | N/A |
| 12/31/2019 | 0 | -17 | -13 | -13 | N/A |
| 9/30/2019 | 0 | -17 | -14 | -14 | N/A |
| 6/30/2019 | 0 | -16 | -14 | -14 | N/A |
| 3/31/2019 | 0 | -19 | -14 | -14 | N/A |
| 12/31/2018 | 0 | -19 | -13 | -13 | N/A |
| 9/30/2018 | 0 | -18 | -13 | -13 | N/A |
| 6/30/2018 | 1 | -18 | -16 | -16 | N/A |
| 3/31/2018 | 1 | -20 | N/A | -17 | N/A |
| 12/31/2017 | 1 | -25 | N/A | -23 | N/A |
| 9/30/2017 | 0 | -31 | N/A | -29 | N/A |
| 6/30/2017 | 0 | -37 | N/A | -29 | N/A |
| 3/31/2017 | 0 | -39 | N/A | -33 | N/A |
| 12/31/2016 | 0 | -39 | N/A | -31 | N/A |
| 9/30/2016 | 0 | -38 | N/A | -29 | N/A |
| 6/30/2016 | 0 | -31 | N/A | -27 | N/A |
| 3/31/2016 | 0 | -31 | N/A | -24 | N/A |
| 12/31/2015 | 0 | -27 | N/A | -22 | N/A |
| 9/30/2015 | 0 | -25 | N/A | -19 | N/A |
| 6/30/2015 | 0 | -27 | N/A | -17 | N/A |
| 3/31/2015 | 0 | -18 | N/A | -15 | N/A |
| 12/31/2014 | 0 | -14 | N/A | -13 | N/A |
| 9/30/2014 | 0 | -11 | N/A | -11 | N/A |
| 6/30/2014 | 0 | -10 | N/A | -9 | N/A |
| 3/31/2014 | 0 | -14 | N/A | -8 | N/A |
| 12/31/2013 | 0 | -12 | N/A | -7 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: CRDF is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: CRDF is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: CRDF is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: CRDF's revenue is expected to decline over the next 3 years (-32.6% per year).
Yüksek Büyüme Geliri: CRDF's revenue is forecast to decline over the next 3 years (-32.6% per year).
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if CRDF's Return on Equity is forecast to be high in 3 years time